Chiral drugs : chemistry and biological action /
"This book overviews chiral drugs and their impact in the pharmaceutical industry. The chapters detail basics and trends in chiral drug discovery and development, as well as techniques / skills and trends of asymmetric synthesis. The first section introduces the general concept of chirality and its...
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Buch |
| Sprache: | Englisch |
| Veröffentlicht: |
Hoboken, N.J.
Wiley
2011.
|
| Schlagworte: | |
| Online-Zugang: | Im OPAC anzeigen |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|
MARC
| LEADER | 00000cam a22000004a 4500 | ||
|---|---|---|---|
| 005 | 20260127134104.0 | ||
| 008 | 120914s2011 njua b 001 0 eng | ||
| 010 | |a 2011-002203 | ||
| 016 | 7 | |a 101553011 |2 DNLM | |
| 016 | 7 | |a 015905908 |2 Uk | |
| 020 | |a 9780470587201 (hardback) | ||
| 020 | |a 0470587202 (hardback) | ||
| 020 | |a 9781118075647 (oBook) | ||
| 020 | |a 1118075641 (oBook) | ||
| 020 | |a 9781118075623 (ePDF) | ||
| 020 | |a 1118075625 (ePDF) | ||
| 020 | |a 9781118075630 (ePub) | ||
| 020 | |a 1118075633 (ePub) | ||
| 035 | |a vtls010450088 | ||
| 039 | 9 | |y 201209140915 |z mschk03 | |
| 040 | |a DNLM/DLC |c DLC |d YDX |d NLM |d YDXCP |d CDX |d UKMGB |d DLC |d STUSCHK1 | ||
| 042 | |a pcc | ||
| 060 | 0 | 0 | |a 2011 K-301 |
| 060 | 1 | 0 | |a QV 744 |
| 082 | 0 | 0 | |a 615/.19 |2 22 |
| 245 | 0 | 0 | |a Chiral drugs : |b chemistry and biological action / |c edited by Guo-Qiang Lin, Qi-Dong You, Jie-Fei Cheng. |
| 260 | |a Hoboken, N.J. |b Wiley |c 2011. | ||
| 300 | |a x, 456 p. |b ill. |c 25 cm. | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 8 | |a Machine generated contents note: Chapter 1. Overview of chirality and chiral drugs (Guo-Qiang Lin, Jiange Zhang and Jie-Fei Cheng). -- Chapter 2. Chiral drugs through asymmetric synthesis (Guo-Quiang Lin and Xing-Wen Sun). -- Chapter 3. Chiral drugs via biocatalytical approaches (Jianqiang Wang and Wenya Lu). -- Chapter 4. Chiral resolution (Qi-Dong You). -- Chapter 5. Fluorine-containing chiral drugs (Xiao-Long Qiu, Xuyi Yue and Feng-Ling Qing). -- Chapter 6. Industrial application of chiral technologies (Hui-Ying (Harry) Li, Rui Liu, Carl Behrens, and Chao-Ying Ni). -- Chapter 7. Computation modeling study on mechanism-of-action of chiral drugs (Deping Wang and Eric Gu). -- Chapter 8. Pharmacology of chiral drugs (Yongge Liu and Xiao-Hui Gu). -- Chapter 9. Pharmacokinetics of chiral drugs (Hanqing Dong, Xiaochuan Guo and Zengbiao Li). -- Chapter 10. Toxicology of chiral drugs (Guang Yang and Hai-Zhi Bu). -- Chapter 11. Representative chiral drugs (Jiangqin Sun, Dingguo Liu and Zhimin Wang). | |
| 520 | |a "This book overviews chiral drugs and their impact in the pharmaceutical industry. The chapters detail basics and trends in chiral drug discovery and development, as well as techniques / skills and trends of asymmetric synthesis. The first section introduces the general concept of chirality and its impact on the drug discovery and development. This part includes history of chiral drug development, key technologies for preparation of chiral drugs, and industrial applications of chiral technologies"--Provided by publisher. | ||
| 650 | 0 | |a Chiral drugs. | |
| 650 | 0 | |a Drug development. | |
| 650 | 0 | |a Structure-activity relationships (Biochemistry) | |
| 650 | 1 | 2 | |a Drug Discovery |x methods. |
| 650 | 2 | 2 | |a Pharmaceutical Preparations |x chemistry. |
| 650 | 2 | 2 | |a Structure-Activity Relationship. |
| 700 | 1 | |a Lin, Guo-Qiang, |d 1943- | |
| 700 | 1 | |a You, Qi-Dong. | |
| 700 | 1 | |a Cheng, Jie-Fei. | |
| 906 | |a 7 |b cbc |c orignew |d 1 |e ecip |f 20 |g y-gencatlg | ||
| 910 | |a SCHK95 | ||
| 919 | |a 978-0-470-58720-1 | ||
| 925 | 0 | |a acquire |b 2 shelf copies |x policy default | |
| 955 | |d xh07 2011-02-14 to Dewey |w rd13 2011-02-15 |f xj04 2012-01-13 Z-CipVer | ||
| 955 | |d xh07 2011-02-14 to Dewey |w rd13 2011-02-15 | ||
| 963 | |a Elizabeth Vigier; phone: 201-748-6577; email: evigier@wiley.com; bc: mschell@wiley.com | ||
| 985 | |a NLMCIP |d 2011-02-03 | ||
| 999 | |c 3802 |d 3802 | ||